Video

Exploring Therapeutic Vaccine in Head and Neck Cancer

Author(s):

Joshua Bauml, M.D.

Joshua Bauml, M.D., assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the potential of therapeutic vaccine in patients who have head and neck cancer.

Joshua Bauml, M.D., assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the potential of therapeutic vaccine in patients who have head and neck cancer.

Human papillomavirus-driven cancers have predictable epitopes, which are recognized by the immune system, that can be targeted. So, a recent study targeted the E6 and E7 epitopes and found that these patients did spark an immune response.

Looking forward, Bauml said that T-cell based therapies might have a place in this treatment arena, as well as combinations including immunotherapy agents.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Image of two doctors and text.
Related Content
Keytruda was approved for locally advanced head and neck cancer before and after surgery: © stock.adobe.com.
June 12th 2025

FDA Approves Perioperative Keytruda for Locally Advanced Head and Neck Cancer

Spencer Feldman
Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Image of neck.
May 23rd 2025

GLP-1 Drugs Linked to Fewer Obesity-Related Cancers

Ariana Pelosci
GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
Illustration of neck.
April 25th 2025

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

Alex Biese
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.